Wedbush Expects Reduced Earnings for Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Analysts at Wedbush lowered their FY2027 earnings estimates for shares of Apellis Pharmaceuticals in a report released on Tuesday, October 14th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.33) for the year, down from their prior forecast of $0.12. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ FY2028 earnings at $0.92 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.11. The business had revenue of $171.39 million for the quarter, compared to analyst estimates of $187.91 million. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. The business’s quarterly revenue was down 10.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.30) EPS.

APLS has been the topic of several other research reports. Raymond James Financial reduced their target price on shares of Apellis Pharmaceuticals from $52.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, August 1st. Robert W. Baird boosted their price objective on shares of Apellis Pharmaceuticals from $47.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, July 18th. Wells Fargo & Company started coverage on shares of Apellis Pharmaceuticals in a report on Wednesday. They issued an “overweight” rating and a $32.00 price objective on the stock. Morgan Stanley boosted their price objective on shares of Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 2nd. Finally, Bank of America boosted their price objective on shares of Apellis Pharmaceuticals from $23.00 to $24.00 and gave the stock a “neutral” rating in a report on Wednesday, July 16th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $33.47.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $24.15 on Thursday. The company has a current ratio of 3.77, a quick ratio of 3.16 and a debt-to-equity ratio of 2.90. The firm has a market capitalization of $3.05 billion, a price-to-earnings ratio of -13.27 and a beta of 0.69. The firm’s fifty day simple moving average is $25.38 and its 200 day simple moving average is $21.17. Apellis Pharmaceuticals has a twelve month low of $16.10 and a twelve month high of $35.72.

Insider Transactions at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 31,092 shares of the business’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $23.72, for a total transaction of $737,502.24. Following the completion of the sale, the director owned 3,837 shares of the company’s stock, valued at $91,013.64. This represents a 89.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Cedric Francois sold 49,963 shares of the business’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $28.39, for a total transaction of $1,418,449.57. Following the sale, the chief executive officer directly owned 307,946 shares of the company’s stock, valued at approximately $8,742,586.94. This represents a 13.96% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 297,921 shares of company stock valued at $8,084,466. Insiders own 6.50% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently modified their holdings of APLS. Assetmark Inc. grew its position in shares of Apellis Pharmaceuticals by 3,938.7% during the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock valued at $27,000 after buying an additional 1,221 shares during the last quarter. Parallel Advisors LLC grew its position in Apellis Pharmaceuticals by 80.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after purchasing an additional 855 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after acquiring an additional 1,570 shares in the last quarter. GF Fund Management CO. LTD. boosted its holdings in shares of Apellis Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock valued at $70,000 after acquiring an additional 573 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Apellis Pharmaceuticals by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock valued at $84,000 after acquiring an additional 655 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).